Aimmune to present AR101 and peanut allergy data at AAAAI

Aimmune Therapeutics announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology Annual Meeting, taking place February 22-25 in San Francisco. “We are excited by the new data being presented at AAAAI, which deepen our understanding of AR101 and how it may benefit children, teens and families struggling with the uncertainty of life with peanut allergy,” said Daniel Adelman, M.D., Chief Medical Officer of Aimmune. “Our goal with AR101 oral immunotherapy is to train the immune system so that allergic reactions with accidental exposures are less frequent and severe. Taken together, the new data presented at AAAAI help to elucidate how AR101 delivers on our therapeutic thesis, providing continued immunomodulation throughout the course of the treatment period studied, as evidenced by greatly reduced adverse events due to accidental exposures to peanuts. These data provide further evidence of the effects demonstrated in the exit food challenge in PALISADE, with a 94% reduction of epinephrine use in the AR101-treated patients at the 600-mg exit food challenge dose. Also, we are seeing increases in efficacy over time, as nearly two thirds of the AR101 patients who tolerated less than the highest dose at the PALISADE exit were able to tolerate more peanut protein in the follow-on study challenge, and half the patients overall were able to tolerate 2,000 mg as the single highest tolerated dose.”
https://thefly.com/landingPageNews.php?id=2858465